“Safe” dose thrombolytics for PE

Concerns continue to exist in using thrombolytics for patients with PE. This trial enrolled patients with symptomatic moderate PE (>70% involvement of at least 2 lobes, or 1 main pulmonary artery). TPA was given as a 10mg bolus, then 40mg over 2 hours (or 0.5mg/kg for those <50kg). After ~2 years, pulmonary HTN was present in 16% of the thrombolytic group and 57% of the control group, mean hospital stay was shorter (2.2 vs 4.9 days), and there were no differences between the groups in mortality or bleeding (abstract).

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment